Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS MUTATION
KRAS MUTATION - Associated Disease
- pancreatic adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition. Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either agent alone. Chemical library screen in two cell lines also identified mTOR, AKT Family Inhibitors (Temsirolimus, Everolimus) to act synergistically with ERK Inhibition.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1003
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/336
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Pancreatic Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- SCH772984,PI3Kbeta Inhibitor AZD8186
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26725216
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| PI3Kbeta Inhibitor AZD8186 | Sensitivity | true |
| SCH772984 | Sensitivity | true |